

GENTA INC DE/  
Form 8-K  
May 17, 2005

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, DC 20549**

---

**FORM 8-K**

**CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): May 17, 2005

**GENTA INCORPORATED**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**

(State or Other Jurisdiction of Incorporation)

**0-19635**

(Commission File Number)

**33-0326866**

(IRS Employer Identification No.)

**Two Connell Drive  
Berkeley Heights, NJ**

(Address of Principal Executive Offices)

**07922**

(Zip Code)

**(908) 286-9800**

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-



**Item 8.01 Other Events.**

On May 17, 2005 Genta Incorporated ( Genta ) issued a press release announcing the release of data from multiple clinical studies using Genasense® (oblimersen sodium) Injection in combination with various types of chemotherapy in patients with advanced gastrointestinal (GI) cancers.

On May 17, 2005 Genta issued a press release announcing the release of data from studies of Genasense® in combination with chemotherapy for children with solid tumors and adults with extensive-stage small cell lung cancer and advanced hormone-refractory prostate cancer.

The press releases are attached hereto as Exhibit 99.1 and 99.2 and incorporated herein by reference.

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release dated May 17, 2005
99.2	Press Release dated May 17, 2005

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GENTA INCORPORATED

Date: May 17, 2005

By: /s/ William P. Keane

Name: William P. Keane  
Title: Senior Vice President, Chief  
Financial Officer and Corporate  
Secretary

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description</b>	<b>Sequentially Numbered Page</b>
99.1	Press Release dated May 17, 2005	
99.2	Press Release dated May 17, 2005	

---